Department of Infectious Diseases, Saint Louis Hospital, University of Paris Diderot, France.
AIDS Patient Care STDS. 2011 Aug;25(8):457-60. doi: 10.1089/apc.2011.0056. Epub 2011 Jul 13.
We report a 46-year-old man who has sex with men (MSM) patient, of Scottish descent, who had no history of arterial hypertension, diabetes, or illicit drug use, was hepatitis C virus (HCV) negative but underwent right nephrectomy for urothelial tumor in 2006. Before starting antiretroviral therapy, he had a CD4 cell count of 316/mm(3) and plasma HIV RNA level was 1,020,537 copies per milliliter. He developed acute renal failure only 2 weeks after introduction of tenofovir-based antiretroviral therapy and then required 3 months of hemodialysis. After the end of hemodialysis, antiviral therapy was resumed with abacavir (300 mg×2/day), lamivudine (300 mg every day), and lopinavir/ritonavir (400/100 mg twice daily). Renal biopsy revealed severe and diffuse toxic acute tubular necrosis Two years after tenofovir discontinuation, the patient's renal function remained subnormal. Although severe renal toxicity due to tenofovir is rare, patients receiving tenofovir must be monitored closely for renal dysfunction especially during the first weeks of tenofovir therapy.
我们报告了一例 46 岁的男男性行为者(MSM)患者,他没有动脉高血压、糖尿病或非法药物使用史,丙型肝炎病毒(HCV)阴性,但在 2006 年因尿路上皮肿瘤接受了右肾切除术。开始抗逆转录病毒治疗前,他的 CD4 细胞计数为 316/mm³,血浆 HIV RNA 水平为每毫升 1,020,537 拷贝。他在开始使用基于替诺福韦的抗逆转录病毒治疗后仅 2 周就出现急性肾衰竭,随后需要进行 3 个月的血液透析。血液透析结束后,重新开始使用阿巴卡韦(300mg×2/天)、拉米夫定(300mg 每天)和洛匹那韦/利托那韦(400/100mg 每天两次)进行抗病毒治疗。肾活检显示严重弥漫性急性肾小管坏死。停用替诺福韦两年后,患者的肾功能仍未恢复正常。尽管替诺福韦引起的严重肾毒性很少见,但接受替诺福韦治疗的患者必须密切监测肾功能,特别是在替诺福韦治疗的最初几周。